chr1-44828037-G-T
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2
The NM_003738.5(PTCH2):c.1864C>A(p.His622Asn) variant causes a missense change. The variant allele was found at a frequency of 0.00339 in 1,614,192 control chromosomes in the GnomAD database, including 15 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. H622Y) has been classified as Likely benign.
Frequency
Consequence
NM_003738.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PTCH2 | NM_003738.5 | c.1864C>A | p.His622Asn | missense_variant | 14/22 | ENST00000372192.4 | NP_003729.3 | |
PTCH2 | NM_001166292.2 | c.1864C>A | p.His622Asn | missense_variant | 14/23 | NP_001159764.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PTCH2 | ENST00000372192.4 | c.1864C>A | p.His622Asn | missense_variant | 14/22 | 1 | NM_003738.5 | ENSP00000361266.3 | ||
PTCH2 | ENST00000447098.6 | c.1864C>A | p.His622Asn | missense_variant | 14/23 | 1 | ENSP00000389703.2 |
Frequencies
GnomAD3 genomes AF: 0.00235 AC: 358AN: 152236Hom.: 1 Cov.: 33
GnomAD3 exomes AF: 0.00224 AC: 561AN: 250818Hom.: 1 AF XY: 0.00209 AC XY: 283AN XY: 135624
GnomAD4 exome AF: 0.00350 AC: 5121AN: 1461838Hom.: 14 Cov.: 58 AF XY: 0.00336 AC XY: 2447AN XY: 727226
GnomAD4 genome AF: 0.00234 AC: 357AN: 152354Hom.: 1 Cov.: 33 AF XY: 0.00234 AC XY: 174AN XY: 74494
ClinVar
Submissions by phenotype
not provided Benign:5
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Oct 08, 2020 | - - |
Likely benign, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The PTCH2 p.His622Asn variant was not identified in the literature nor was it identified in Cosmic. The variant was identified in dbSNP (ID: rs11573586), LOVD 3.0 (classified as likely benign) and in ClinVar (classified as likely benign by Division of Genomic Diagnostics, The Children's Hospital of Philadelphia and as benign by Invitae). The variant was also identified in control databases in 644 of 282218 chromosomes (1 homozygous) at a frequency of 0.002282 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017) and was observed in the following populations: European (Finnish) in 180 of 25086 chromosomes (freq: 0.007175), European (non-Finnish) in 416 of 128572 chromosomes (freq: 0.003236), Other in 12 of 7220 chromosomes (freq: 0.001662), African in 29 of 24968 chromosomes (freq: 0.001161) and Latino in 7 of 35434 chromosomes (freq: 0.000198), while the variant was not observed in the Ashkenazi Jewish, East Asian and South Asian populations. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. The p.His622 residue is not conserved in mammals and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2024 | PTCH2: BS2 - |
not specified Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | Nov 20, 2015 | - - |
Benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
PTCH2-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 18, 2020 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Gorlin syndrome Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at